genedrive plc (AIM: GDR), the near patient molecular diagnostics company, announces its audited Final Results for the year ended 30 June 2021.
Genedrive PLC (GDR.L) Result of Open Offer
London, UK – 29 September 2021: genedrive plc (LSE: GDR), the near-patient molecular diagnostics company, announces that it has conditionally raised total gross proceeds of approximately £1.1 million through the
Genedrive PLC (GDR.L) New Genedrive system readied for AIHL launch
New Genedrive® system readied for Antibiotic Induced Hearing Loss launch
Genedrive PLC (GDR.L) Genedrive® COVID-19 Point of Care device update
genedrive plc (AIM: GDR), the near-patient molecular diagnostics company, provides an update on the development of its Genedrive® COV19-ID Kit, a rapid Point of Care (PoC) molecular test for SARS-CoV-2
Genedrive PLC (GDR.L) COVID-19 PCR test approved by Indian regulator
Genedrive plc (AIM: GDR), the near patient molecular diagnostics company, announces that the Genedrive® 96 SARS-CoV-2 Kit has been formally approved by the Indian Council of Medical Research (“ICMR”).
Genedrive PLC (GDR.L) Excellent performance data for Genedrive® HCV test
Excellent performance of Genedrive®HCV -ID Kit in large multi-centre study
Genedrive PLC (GDR.L) PHE National Framework Agreement
Genedrive successful in PHE National Framework Agreement for Diagnostics Goods and Services
Genedrive PLC (GDR.L) Half Year Report
genedrive plc (LSE: GDR), the near-patient molecular diagnostics company, announces unaudited interim results for the six months to 31 December 2020.
Genedrive PLC (GDR.L) Distribution agreement
Genedrive enters distribution agreement with Mountain Horse Solutions
Genedrive PLC (GDR.L) Antibiotic Induced Hearing Loss update
New clinical guidance in the UK supports assay